Insider Transactions in Q1 2025 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$86,000
$43.58 P/Share
|
|
Mar 18
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Mar 17
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
37,648
-5.3%
|
$1,656,512
$44.52 P/Share
|
|
Mar 17
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
4,389
-4.16%
|
$193,116
$44.38 P/Share
|
|
Mar 17
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
23,675
-21.53%
|
$1,041,700
$44.76 P/Share
|
|
Mar 17
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,900
+26.3%
|
$480,700
$23.26 P/Share
|
|
Mar 14
2025
|
Sung Lee EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,687
+30.51%
|
-
|
|
Mar 14
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,687
+31.72%
|
-
|
|
Mar 14
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
39,450
+21.41%
|
-
|
|
Mar 14
2025
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
116,096
+19.47%
|
-
|
|
Mar 14
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
100
-0.26%
|
$4,500
$45.0 P/Share
|
|
Mar 14
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.26%
|
$2,300
$23.26 P/Share
|
|
Mar 13
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
26,771
-41.55%
|
$1,151,153
$43.62 P/Share
|
|
Mar 06
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
8,228
-7.24%
|
$353,804
$43.27 P/Share
|
|
Mar 06
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,341
-4.93%
|
$143,663
$43.27 P/Share
|
|
Mar 06
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
16,970
-4.45%
|
$729,710
$43.44 P/Share
|
|
Mar 05
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
25,000
-6.16%
|
$1,075,000
$43.23 P/Share
|
|
Mar 04
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.69%
|
$84,000
$42.5 P/Share
|
|
Mar 04
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.67%
|
$20,000
$10.6 P/Share
|
|
Mar 04
2025
|
Robert Arthur Harrington Director |
SELL
Open market or private sale
|
Direct |
900
-5.62%
|
$37,800
$42.5 P/Share
|
|
Mar 03
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,114
-1.62%
|
$46,788
$42.88 P/Share
|
|
Mar 03
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,449
-2.11%
|
$102,858
$42.88 P/Share
|
|
Mar 03
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
8,743
-2.11%
|
$367,206
$42.88 P/Share
|
|
Feb 18
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.69%
|
$90,000
$45.98 P/Share
|
|
Feb 18
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.67%
|
$20,000
$10.6 P/Share
|
|
Feb 04
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.69%
|
$96,000
$48.06 P/Share
|
|
Feb 04
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.67%
|
$20,000
$10.6 P/Share
|
|
Jan 21
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.69%
|
$90,000
$45.92 P/Share
|
|
Jan 21
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.67%
|
$20,000
$10.6 P/Share
|
|
Jan 07
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.69%
|
$98,000
$49.32 P/Share
|
|
Jan 07
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.67%
|
$20,000
$10.6 P/Share
|
|
Jan 02
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
255
+0.98%
|
$12,240
$48.93 P/Share
|
|
Jan 02
2025
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
255
+1.57%
|
$12,240
$48.93 P/Share
|
|
Jan 02
2025
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
434
+0.88%
|
$20,832
$48.93 P/Share
|
|
Jan 02
2025
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
127
+0.51%
|
$6,096
$48.93 P/Share
|
|
Jan 02
2025
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
127
+0.55%
|
$6,096
$48.93 P/Share
|